Vertex Pharma has claimed an ultra-fast approval in the US for Trikafta, its three-drug combination that provides a treatment option for up to 90% of patients with the genetic disease cystic fibrosis.

Vertex Pharmaceuticals VRTX announced that the European Commission (EC) has expanded the label of its blockbuster cystic ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

Listed below are the charts and positions for Trikafta/Kaftrio in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Trikafta/Kaftrio. GlobalData provides trusted ...

When I was first diagnosed with CF, I wasn’t supposed to live past the age of 8. Then Trikafta gave me the chance for a future I wasn’t prepared for. I’ve built a new life for myself and learned to ...

Subsequent approvals throughout the decade led up to a major medical innovation in the form of Trikafta, a triple-combination drug from Vertex Pharmaceuticals that changed the game for around 90% ...

Vertex Pharmaceuticals today announced that the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has granted consent for the expanded use of ...

It markets several CF treatments, including TRIKAFTA/KAFTRIO, ALYFTREK, and ORKAMBI, and is also developing therapies for sickle cell disease, type 1 diabetes, and other conditions. The Boston ...

Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is driving record sales. The company is also poised to benefit from two ...